- Ortho's VITROS ®  Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization of SARS-CoV-2 serological methods - The test gives clinicians and public health leaders a

ORTHO VISION is the leading choice for blood banks RARITAN, N.J. , May 3, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ORTHO VISION ® Swift and ORTHO VISION ® Max

Silver Award Recognizes Antibody and Antigen Tests RARITAN, N.J. , April 26, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics  (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious silver 2021 Edison Award for its  VITROS ®

RARITAN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2021 ended April 4, 2021, after the market close on May 5, 2021.

RARITAN, N.J. , April 13, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020 . The CE Mark allows

- The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months  RARITAN, N.J. , March 31, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's

RARITAN, N.J. , March 23, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2

Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1% RARITAN, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial results for the fourth

- Ortho's new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune response (acquired naturally or through vaccination) to SARS-CoV-2 - These new anti-SARS-CoV-2

RARITAN, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care, today announced it will report results for the fourth quarter and full year